Moreover, a meta-analysis comparing GnRH antagonists and agonists reported that cetrorelix significantly reduced the risk of OHSS (OR = 0.23) compared to long-term GnRH agonist regimens, whereas ganirelix did not (OR = 1.13) [44]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.